





151691

BLACK & ELLIOTT



HYPERTENSION

A Companion to Braunwald's
HEART DISEASE



Contents

SECTION 1: Epidemiology and Pathophysiology, 1

1. Epidemiology of Hypertension, 3
Donald M. Lloyd-Jones and Daniel Levy
2. Genetics of Hypertension, 15
Xiaodong Wu and Richard S. Cooper
3. Pathophysiology of Hypertension, 25
Veronica Franco, David A. Calhoun, and Suzanne Oparil

SECTION 2: Diagnosis, 47

4. Defining Hypertension, 49
Theodore A. Kotchen and Jane Morley Kotchen
5. Office Blood Pressure Measurement, 58
Clarence E. Grim and Carlene M. Grim
6. Home Monitoring of Blood Pressure, 69
Thomas G. Pickering
7. Ambulatory Blood Pressure Monitoring in Hypertension, 85
William B. White
8. Secondary Hypertension: Renovascular Hypertension, 93
William J. Elliott
9. Secondary Hypertension: Mineralocorticoid Excess States, 106
Emmanuel L. Bravo
10. Secondary Hypertension: Pheochromocytoma, 119
William F. Young, Jr.
11. Secondary Hypertension: Sleep Apnea, 134
Gianfranco Parati, Grzegorz Bilo, Carolina Lombardi, and Giuseppe Mancia
12. Rare and Unusual Forms of Hypertension, 144
Ehud Grossman and Franz H. Messerli

SECTION 3: Risk Stratification, 153

13. The Natural History of Untreated Hypertension, 155
William J. Elliott
14. The Special Problem of Isolated Systolic Hypertension, 169
Stanley S. Franklin
15. Assessment of Hypertensive Target Organ Damage, 178
Joseph L. Izzo, Jr., Philip R. Liebson, Philip B. Gorelick, James J. Reidy, and Albert Mimran
16. Prediction of Global Cardiovascular Risk in Hypertension, 190
Peter W. F. Wilson

SECTION 4: Treatment, 199

17. Diet and Blood Pressure, 201
Lawrence J. Appel
18. Diuretic Therapy in Cardiovascular Disease, 213
Domenic A. Sica and Marvin Moser
19. β -Blockers in Hypertension, 231
William H. Frishman
20. Angiotensin-Converting Enzyme Inhibitors, 239
Domenic A. Sica
21. Angiotensin Receptor Blockers, 254
William J. Elliott and Henry R. Black
22. Calcium Channel Blockers in Hypertension, 268
Alberto Zanchetti
23. α -Blockers, 286
William J. Elliott and James L. Pool
24. New and Investigational Drugs for Hypertension, 295
Alexander M. M. Shepherd

SECTION 5: Outcome Studies, 303

- 25.** Design of Outcomes Studies, 305
James D. Neaton
- 26.** Meta-analyses of Hypertension Trials, 316
Fiona Turnbull and Bruce Neal

SECTION 6: Hypertension and Concomitant Diseases, 325

- 27.** Ischemic Heart Disease in Hypertension, 327
Clive Rosendorff
- 28.** Heart Failure in Hypertension, 340
Ronald S. Freudenberger and John B. Kostis
- 29.** Kidney Disease in Hypertension, 351
Kenneth L. Choi and George L. Bakris
- 30.** Transplant Hypertension, 361
Sandra J. Taler
- 31.** Obesity in Hypertension, 370
F. Xavier Pi-Sunyer and Panagiotis Kokkoris
- 32.** Peripheral Arterial Disease in Hypertension, 384
Michael H. Criqui and Matthew A. Allison
- 33.** Cerebrovascular Disease in Hypertension, 392
Neil Chapman, Craig Anderson, and John Chalmers
- 34.** Hypertension and Diabetes Mellitus, 406
Maryann N. Mugo, Craig S. Stump, Priya G. Rao, and James R. Sowers
- 35.** Dyslipidemia in Hypertension, 418
John C. LaRosa

SECTION 7: Special Populations and Special Situations, 427

- 36.** Hypertension in Pregnancy, 429
Tiina Podymow and Phyllis August
- 37.** Hypertension in Children and Adolescents, 440
Bonita Falkner

- 38.** Hypertension in the Elderly, 457
Michael J. Bloch and Jan N. Basile
- 39.** Hypertension in African Americans, 468
John M. Flack, Tariq Shafi, Shalini Chandra, Jason Ramos, Samar A. Nasser, and Errol D. Crook
- 40.** Hypertension in Hispanics, 482
David J. Hyman, Carlos Vallbona, Paul Pisarik, and Valory N. Pavlik
- 41.** Hypertension in East Asians and Pacific Islanders, 487
Nathan D. Wong
- 42.** Hypertension in South Asians, 493
Prakash C. Deedwania and Rajeev Gupta
- 43.** Resistant Hypertension, 498
John F. Setaro
- 44.** Hypertension and the Perioperative Period, 512
Robert L. Bard, Robert D. Brook, and Kim A. Eagle
- 45.** Hypertensive Emergencies and Urgencies, 517
Shakaib U. Rehman, Jan N. Basile, and Donald G. Vidt

SECTION 8: Hypertension Treatment in the Future, 525

- 46.** Hypertension Disease Management Services, 527
Barry L. Carter
- 47.** Antihypertensive Drug Development: A Regulatory Perspective, 535
Mehul G. Desai, Norman Stockbridge, Douglas C. Throckmorton, and Robert Temple

SECTION 9: Guidelines, 549

- 48.** U.S. and Canadian Guidelines for Hypertension, 551
Larry E. Fields
- 49.** European, American, and British Guidelines: Similarities and Differences, 571
Giuseppe Mancina and Guido Grassi

INDEX, 577